Bacterial Conjunctivitis ' Pipeline Review, H2 2012

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

Bacterial Conjunctivitis ' Pipeline Review, H2 2012
Published on December 2012

Report Summary


Summary

Global Markets Direct's, 'Bacterial Conjunctivitis - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic
pipeline. This report provides information on the therapeutic development for Bacterial Conjunctivitis, complete with latest updates,
and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for
Bacterial Conjunctivitis. Bacterial Conjunctivitis - Pipeline Review, Half Year is built using data and information sourced from Global
Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases
from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated
disease.

Scope

- A snapshot of the global therapeutic scenario for Bacterial Conjunctivitis.
- A review of the Bacterial Conjunctivitis products under development by companies and universities/research institutes based on
information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Bacterial Conjunctivitis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Bacterial Conjunctivitis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive
advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Bacterial Conjunctivitis pipeline depth and focus of Indication
therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Bacterial Conjunctivitis ' Pipeline Review, H2 2012 (From Slideshare) Page 1/6


Table of Content

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Bacterial Conjunctivitis Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Bacterial Conjunctivitis 7
Bacterial Conjunctivitis Therapeutics under Development by Companies 9
Late Stage Products 10
Comparative Analysis 10
Discovery and Pre-Clinical Stage Products 11
Comparative Analysis 11
Bacterial Conjunctivitis Therapeutics ' Products under Development by Companies 12
Companies Involved in Bacterial Conjunctivitis Therapeutics Development 13
InSite Vision Incorporated 13
NovaBay Pharmaceuticals, Inc. 14
LABORATOIRES THEA 15
Bacterial Conjunctivitis ' Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Drug Profiles 21
azithromycin - Drug Profile 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
azithromycin - Drug Profile 22
R&D Progress 22
NVC-727 - Drug Profile 23
R&D Progress 23
R&D Progress 24
R&D Progress 25



EGP-Antibiotics - Drug Profile 26
R&D Progress 26
Bacterial Conjunctivitis Therapeutics - Dormant Products 27
Bacterial Conjunctivitis ' Product Development Milestones 28
Featured News & Press Releases 28
Nov 08, 2012: Bausch + Lomb To Present Data On Besifloxacin Ophthalmic Suspension At American Academy of Ophthalmology
Annual Meeting 28
Jan 05, 2012: University Of California, San Francisco Files Appeal Of USPTO Judgment In Favor Of InSite Vision 28
Nov 28, 2011: InSite Vision Wins Patent Interference Litigation Against University Of California, San Francisco 28
Oct 18, 2010: Garamycin Ophthalmic Ointment Now Available from Fera Pharmaceuticals 29
Sep 22, 2010: Alcon Launches TobraDex ST Suspension In US 29
Dec 17, 2009: NovaBay To Receive Increase In Funding And Support From Alcon 29
Jun 02, 2009: InSite Vision Announces FDA Approval of New Ophthalmic Product Enabled by InSite's DuraSite(R) Technology 30
May 29, 2009: Bausch & Lomb Receives FDA Approval of Besivance, New Topical Ophthalmic Antibacterial for the Treatment of
Bacterial Conjunctivitis ('Pink Eye') 30
Dec 05, 2008: FDA Advisory Committee Recommends Approval of Bausch & Lomb Besifloxacin Anti-Infective Eye Drop 31
Jul 19, 2005: Select Access to Co-Promote Allergan's Zymar to Primary Care Physicians. 31
Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 33
Disclaimer 33

List of Tables

Number of Products Under Development for Bacterial Conjunctivitis, H2 2012 7
Products under Development for Bacterial Conjunctivitis ' Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Comparative Analysis by Late Stage Development, H2 2012 10
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 11
Products under Development by Companies, H2 2012 12
InSite Vision Incorporated, H2 2012 13
NovaBay Pharmaceuticals, Inc., H2 2012 14
LABORATOIRES THEA, H2 2012 15
Assessment by Monotherapy Products, H2 2012 16
Assessment by Stage and Route of Administration, H2 2012 18
Assessment by Stage and Molecule Type, H2 2012 20
Bacterial Conjunctivitis Therapeutics ' Dormant Products 27



List of Figures

Number of Products under Development for Bacterial Conjunctivitis, H2 2012 7
Products under Development for Bacterial Conjunctivitis ' Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Late Stage Products, H2 2012 10
Discovery and Pre-Clinical Stage Products, H2 2012 11
Assessment by Monotherapy Products, H2 2012 16
Assessment by Route of Administration, H2 2012 17
Assessment by Stage and Route of Administration, H2 2012 18
Assessment by Molecule Type, H2 2012 19
Assessment by Stage and Molecule Type, H2 2012 20


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.


Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 2 000.00 Quantity: _____

Site License--USD 4 000.00 Quantity: _____

Corporate License--USD 6 000.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Bacterial Conjunctivitis ' Pipeline Review, H2 2012

Recommended

Recommended

More Related Content

Viewers also liked

Viewers also liked (18)

More from ReportLinker.com

More from ReportLinker.com (20)

Bacterial Conjunctivitis ' Pipeline Review, H2 2012